- Accesswire•27 days agoResearch Reports Initiated on Healthcare Stocks Oncolytics Biotech, ProMetic Life Sciences, Resverlogix, and Helius Medical Technologies
LONDON, UK / ACCESSWIRE / January 26, 2017 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected ...
- PR Newswire•last month
CALGARY, Jan. 19, 2017 /PRNewswire/ - Oncolytics Biotech® Inc. ("Oncolytics" or the "Company") (ONC.TO) (ONCYF) today announced that Matt Coffey PhD, MBA, has been appointed to the role of President and Chief Executive Officer, effective immediately. Dr. Coffey had been serving as the Company's Interim President and Chief Executive Officer since early November 2016. "Dr. Coffey has transitioned seamlessly into his new role and, together with the expanded senior management team, has rapidly crafted plans to advance a range of clinical and operational initiatives," said Wayne Pisano, Chairman of Oncolytics' Board of Directors.
- PR Newswire•3 months ago
CALGARY, Dec. 6, 2016 /PRNewswire/ - Oncolytics Biotech® Inc. ("Oncolytics" or the "Company") (ONC.TO) (ONCYF) today announced that Dr. Brad Thompson has resigned from Oncolytics board of directors effective immediately. Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of later-stage, randomized human trials in various indications using REOLYSIN®, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
ONC.TO : Summary for ONCOLYTICS BIO - Yahoo Finance
Oncolytics Biotech Inc. (ONC.TO)
Toronto - Toronto Delayed Price. Currency in CAD
Add to watchlist
|Day's Range||0.37 - 0.38|
|52 Week Range||0.19 - 0.75|
|PE Ratio (TTM)||-3.27|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|